CN111265565A - A kind of Scutellaria baicalensis dregs semi-solid fermentation technology method and its application - Google Patents
A kind of Scutellaria baicalensis dregs semi-solid fermentation technology method and its application Download PDFInfo
- Publication number
- CN111265565A CN111265565A CN202010188045.1A CN202010188045A CN111265565A CN 111265565 A CN111265565 A CN 111265565A CN 202010188045 A CN202010188045 A CN 202010188045A CN 111265565 A CN111265565 A CN 111265565A
- Authority
- CN
- China
- Prior art keywords
- dregs
- scutellaria baicalensis
- scutellaria
- semi
- solid fermentation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000004534 Scutellaria baicalensis Species 0.000 title claims abstract description 109
- 235000017089 Scutellaria baicalensis Nutrition 0.000 title claims abstract description 109
- 238000000855 fermentation Methods 0.000 title claims abstract description 57
- 230000004151 fermentation Effects 0.000 title claims abstract description 57
- 238000000034 method Methods 0.000 title claims abstract description 35
- 239000007787 solid Substances 0.000 title claims abstract description 30
- 238000005516 engineering process Methods 0.000 title claims description 7
- 239000000203 mixture Substances 0.000 claims abstract description 23
- 239000000843 powder Substances 0.000 claims abstract description 19
- 108090000790 Enzymes Proteins 0.000 claims abstract description 12
- 102000004190 Enzymes Human genes 0.000 claims abstract description 12
- 239000007788 liquid Substances 0.000 claims abstract description 12
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 8
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 8
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 4
- 238000010298 pulverizing process Methods 0.000 claims abstract description 3
- 238000009461 vacuum packaging Methods 0.000 claims abstract description 3
- 229940088598 enzyme Drugs 0.000 claims description 11
- 230000000844 anti-bacterial effect Effects 0.000 claims description 10
- 108010059892 Cellulase Proteins 0.000 claims description 4
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 claims description 4
- 108010059820 Polygalacturonase Proteins 0.000 claims description 4
- 229940106157 cellulase Drugs 0.000 claims description 4
- 108010093305 exopolygalacturonase Proteins 0.000 claims description 4
- 230000003385 bacteriostatic effect Effects 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 14
- 229940079593 drug Drugs 0.000 abstract description 12
- 229930003935 flavonoid Natural products 0.000 abstract description 8
- 150000002215 flavonoids Chemical class 0.000 abstract description 8
- 235000017173 flavonoids Nutrition 0.000 abstract description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract description 6
- 241000894006 Bacteria Species 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 239000000835 fiber Substances 0.000 abstract description 3
- 230000003993 interaction Effects 0.000 abstract description 3
- 239000004310 lactic acid Substances 0.000 abstract description 3
- 235000014655 lactic acid Nutrition 0.000 abstract description 3
- 230000007721 medicinal effect Effects 0.000 abstract description 3
- 239000001814 pectin Substances 0.000 abstract description 3
- 229920001277 pectin Polymers 0.000 abstract description 3
- 235000010987 pectin Nutrition 0.000 abstract description 3
- 239000006041 probiotic Substances 0.000 abstract description 3
- 235000018291 probiotics Nutrition 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 241000207929 Scutellaria Species 0.000 abstract 4
- 238000001035 drying Methods 0.000 abstract 3
- 239000000047 product Substances 0.000 description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 5
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 5
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 5
- 229940015301 baicalein Drugs 0.000 description 5
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 5
- 229960003321 baicalin Drugs 0.000 description 5
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- HIMJIPRMECETLJ-UHFFFAOYSA-N Wogonin Natural products COc1cc(O)c(O)c2C(=O)C=C(Oc12)c3ccccc3 HIMJIPRMECETLJ-UHFFFAOYSA-N 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- XLTFNNCXVBYBSX-UHFFFAOYSA-N wogonin Chemical compound COC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=CC=C1 XLTFNNCXVBYBSX-UHFFFAOYSA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000002893 slag Substances 0.000 description 3
- 241000059485 Escherichia coli O78 Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 239000009916 yin-huang Substances 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- JJMLQAVFDJXJAL-AWZCNKNJSA-N Pyrethrosin Chemical compound CC(=O)O[C@@H]1\C=C(C)\CC[C@H]2O[C@]2(C)C[C@@H]2OC(=O)C(=C)[C@@H]12 JJMLQAVFDJXJAL-AWZCNKNJSA-N 0.000 description 1
- 239000008923 Qingkailing Substances 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000008344 brain blood flow Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000008629 longdanxiegan Substances 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000009254 shuang-huang-lian Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明提供了一种黄芩药渣半固体发酵技术方法,属于半固体发酵技术领域。其技术方案为:取黄芩药渣,黄芩药渣粉碎至20mm以下,得到黄芩药渣粉,将黄芩药渣粉中加入多种复合酶混合物,并充分混合均匀,将充分混合的混合物进行烘干,烘干混合物,将烘干混合物在真空条件下、保持温度在37℃发酵,发酵完成后得到黄芩药渣发酵物并进行真空包装。本发明的有益效果为:利用半固体发酵的方法处理黄芩药渣,所用的液态植物乳杆菌和复合酶会分解黄芩药渣中的纤维、果胶等成分,结合黄芩中的黄酮类有效成分及乳酸菌等多种益生菌的相互作用,不仅能够在比传统的物理化学方法更为温和的条件下实现药渣的利用,更能对其药性进行适度的调整,扩大用药范围。The invention provides a technical method for semi-solid fermentation of Scutellaria baicalensis dregs, belonging to the technical field of semi-solid fermentation. The technical scheme is as follows: taking the scutellaria dregs, pulverizing the scutellaria dregs to less than 20 mm, to obtain the scutellaria dregs powder, adding a variety of compound enzyme mixtures to the scutellaria dregs powder, fully mixing them evenly, and drying the fully mixed mixture , drying the mixture, fermenting the drying mixture under vacuum conditions and keeping the temperature at 37° C., and obtaining Scutellaria baicalensis dregs fermentation product after the fermentation is completed and vacuum-packing. The beneficial effects of the invention are as follows: the semi-solid fermentation method is used to process the scutellaria baicalensis dregs, and the liquid Lactobacillus plantarum and the compound enzyme used can decompose the components such as fiber and pectin in the scutellaria baicalensis dregs, combined with the flavonoids in the scutellaria baicalensis. The interaction of various probiotics such as lactic acid bacteria can not only realize the utilization of medicinal residues under milder conditions than traditional physical and chemical methods, but also moderately adjust their medicinal properties and expand the scope of medication.
Description
技术领域technical field
本发明涉及一种半固体发酵技术领域,尤其涉及一种黄芩药渣半固体发酵技术方法及其应用。The invention relates to the technical field of semi-solid fermentation, in particular to a technical method for semi-solid fermentation of Scutellaria baicalensis dregs and its application.
背景技术Background technique
中药黄芩是唇形科多年生草本植物黄芩的干燥根,主产于黑龙江、吉林、辽宁、河北、山东、陕西、甘肃、内蒙古等地。黄芩具有清热燥湿、泻火解毒、止血安胎的功效,主要用于湿温、暑湿,胸闷呕恶,湿热痞满,泻痢,黄疸,肺热咳嗽,高热烦渴,血热吐衄,痈肿疮毒,胎动不安。黄芩中主要含有黄芩苷、黄芩素、汉黄芩苷、汉黄芩素,此外还有黄芩素-7-O-糖苷,5,7-二羟基 -6-甲氧基双氢黄酮,白杨黄素及其苷,木蝴蝶素A及其葡萄糖醛酸苷等成分。黄芩属于大宗常用药材,据相关资料统计,目前市场上70%的中成药都含有黄芩,如常用的中成药清开灵口服液、双黄连颗粒/口服液/冻干粉针、银黄片/ 银黄颗粒/银黄口服液、小柴胡胶囊/小柴胡片/小柴胡颗粒、龙胆泻肝丸、固经丸等。对于年用量在1.6万吨到2万吨的黄芩来说,黄芩药渣的产量也十分惊人,随着医药产业的蓬勃发展,黄芩药渣的排放量也在日益增加,但对于处理中药药渣大多采取的传统方法如焚烧、固定区域堆放、填埋等方式,不仅使环境遭到巨大破坏,也造成了资源浪费。据有关研究测定,经提取黄芩苷后得到的黄芩药渣中仍含有黄酮类成分,药渣仍然具有抗菌抑菌、抗病毒、抗氧化等作用。The traditional Chinese medicine Scutellaria baicalensis is the dry root of the perennial herb Scutellaria baicalensis, mainly produced in Heilongjiang, Jilin, Liaoning, Hebei, Shandong, Shaanxi, Gansu, Inner Mongolia and other places. Scutellaria baicalensis has the functions of clearing away heat and dampness, purging fire and detoxifying, hemostasis and toxin. , Carbuncle swollen sore, fetal movement restless. Scutellaria baicalensis mainly contains baicalin, baicalein, wogonin, wogonin, in addition to baicalein-7-O-glycoside, 5,7-dihydroxy-6-methoxydihydroflavonoid, chrysanthin and Its glycosides, wood butterfly A and its glucuronide and other components. Scutellaria baicalensis belongs to a large number of commonly used medicinal materials. According to relevant statistics, 70% of Chinese patent medicines on the market currently contain Scutellaria baicalensis, such as commonly used Chinese patent medicines Qingkailing oral liquid, Shuanghuanglian granules/oral liquid/freeze-dried powder injection, Yinhuang tablet/silver Huang Granules/Yinhuang Oral Liquid, Xiao Chai Hu Capsules/ Xiao Chai Hu Tablets/ Xiao Chai Hu Granules, Longdan Xiegan Pills, Gujing Pills, etc. For Scutellaria baicalensis with an annual dosage of 16,000 to 20,000 tons, the output of Scutellaria baicalensis dregs is also very amazing. With the vigorous development of the pharmaceutical industry, the emission of Scutellaria baicalensis dregs is also increasing. Most of the traditional methods adopted, such as incineration, fixed area stacking, landfill, etc., not only cause huge damage to the environment, but also cause waste of resources. According to relevant researches, the scutellaria baicalensis dregs obtained after extraction of baicalin still contain flavonoids, and the dregs still have the functions of antibacterial, antibacterial, antiviral, and antioxidant.
发明内容SUMMARY OF THE INVENTION
本发明的目的在于提供一种利用半固体发酵的方法处理黄芩药渣,所用的微生物和复合酶会分解黄芩药渣中的纤维、果胶等成分,结合黄芩中的黄酮类有效成分及乳酸菌等多种益生菌的相互作用,不仅能够在比传统的物理化学方法更为温和的条件下实现药渣的利用,更能对其药性进行适度的调整,扩大用药范围的黄芩药渣半固体发酵技术方法。The object of the present invention is to provide a method of utilizing semi-solid fermentation to process Scutellaria baicalensis dregs, the microorganisms used and composite enzymes can decompose the components such as fiber and pectin in the Scutellaria baicalensis dregs, combined with flavonoids in Scutellaria baicalensis effective ingredients and lactic acid bacteria etc. The interaction of various probiotics can not only realize the utilization of medicinal residues under milder conditions than traditional physical and chemical methods, but also moderately adjust the medicinal properties and expand the scope of medicine. method.
本发明是通过如下措施实现的:The present invention is achieved by the following measures:
一种黄芩药渣半固体发酵技术方法,其特征在于,所述半固体发酵技术方法包括以下步骤:A technical method for semi-solid fermentation of Scutellaria baicalensis dregs, characterized in that the technical method for semi-solid fermentation comprises the following steps:
S1、取黄芩药渣,将黄芩药渣进行挤压,得到含水率为30%~70%的黄芩药渣;S1, get Scutellaria baicalensis dregs, and Scutellaria baicalensis medicinal dregs are squeezed to obtain the Scutellaria baicalensis medicinal dregs with a moisture content of 30% to 70%;
S2、将S1步骤得到的含水率为30%~70%的黄芩药渣粉碎至20mm以下,将粉碎后的黄芩药渣压滤,得到含水率为30%~60%的黄芩药渣粉;S2, pulverizing the Scutellaria baicalensis dregs with a moisture content of 30% to 70% obtained in step S1 to below 20 mm, and press-filtering the pulverized Scutellaria baicalensis dregs to obtain Scutellaria baicalensis dregs powder with a moisture content of 30% to 60%;
S3、将S2步骤得到含水率为30%~60%的黄芩药渣粉中加入0.3%~0.5%重量比的液态植物乳杆菌和0.3%~0.5%重量比的多种复合酶混合物,并充分混合均匀;S3, adding 0.3% to 0.5% by weight of liquid Lactobacillus plantarum and 0.3% to 0.5% by weight of multiple complex enzyme mixtures to the Scutellaria baicalensis dregs powder with a moisture content of 30% to 60% obtained in step S2, and fully well mixed;
S4、将S3步骤最终得到的混合物在真空条件下、保持温度在37℃发酵7 天,发酵完成后得到黄芩药渣发酵物并进行真空包装。S4. The mixture finally obtained in step S3 is fermented under vacuum conditions and the temperature is kept at 37° C. for 7 days, and after the fermentation is completed, the fermentation product of Scutellaria baicalensis dregs is obtained and vacuum-packed.
本发明的具体特点还有:The specific features of the present invention also include:
所述半固体发酵技术方法包括以下步骤:The semi-solid fermentation technology method comprises the following steps:
S1、取黄芩药渣1kg,将黄芩药渣进行挤压,得到含水率为35%的黄芩药渣;S1, get Scutellaria baicalensis dregs 1kg, Scutellaria baicalensis medicinal dregs are squeezed, obtain the Scutellaria baicalensis medicinal dregs with a moisture content of 35%;
S2、将S1步骤得到的含水率为35%的黄芩药渣粉碎至20mm以下,将粉碎后的黄芩药渣压滤,得到含水率为30%的黄芩药渣粉;S2, the Scutellaria baicalensis dregs with a moisture content of 35% obtained in step S1 is pulverized to less than 20 mm, and the pulverized Scutellaria baicalensis dregs are press-filtered to obtain Scutellaria baicalensis dregs powder with a moisture content of 30%;
S3、将S2步骤得到含水率为30%的黄芩药渣粉中加入0.3%重量比的液态植物乳杆菌和0.3%重量比的多种复合酶混合物,并充分混合均匀;S3, adding 0.3% by weight of liquid Lactobacillus plantarum and 0.3% by weight of multiple composite enzyme mixtures in the Scutellaria baicalensis dregs powder with a moisture content of 30% obtained in step S2, and fully mixed;
S4、将S3步骤最终得到的混合物在真空条件下、保持温度在37℃发酵7 天,发酵完成后得到黄芩药渣发酵物并进行真空包装。S4. The mixture finally obtained in step S3 is fermented under vacuum conditions and the temperature is kept at 37° C. for 7 days, and after the fermentation is completed, the fermentation product of Scutellaria baicalensis dregs is obtained and vacuum-packed.
所述S2步骤中的所述多种复合酶混合物由纤维素酶、果胶酶和木聚糖酶混合组成,所述纤维素酶、所述果胶酶和所述木聚糖酶比例为:2:1:1。The multiple composite enzyme mixture in the step S2 is composed of cellulase, pectinase and xylanase, and the ratio of cellulase, pectinase and xylanase is: 2:1:1.
所述黄芩药渣发酵物用于抗菌抑菌的应用。The Scutellaria baicalensis dregs fermentation product is used for the application of antibacterial and bacteriostasis.
本发明的有益效果为:利用半固体发酵的方法处理黄芩药渣,所用的微生物和复合酶会分解黄芩药渣中的纤维、果胶等成分,结合黄芩中的黄酮类有效成分及乳酸菌等多种益生菌的相互作用,不仅能够在比传统的物理化学方法更为温和的条件下实现药渣的利用,更能对其药性进行适度的调整,扩大用药范围。The beneficial effects of the invention are as follows: using the method of semi-solid fermentation to process the Scutellaria baicalensis dregs, the microorganisms and compound enzymes used can decompose the components such as fiber, pectin and the like in the Scutellaria baicalensis dregs, combined with the flavonoids in the Scutellaria baicalensis effective ingredients and lactic acid bacteria and other components. The interaction of various probiotics can not only realize the utilization of medicinal residues under milder conditions than traditional physical and chemical methods, but also moderately adjust their medicinal properties and expand the scope of medication.
具体实施方式Detailed ways
为能清楚说明本方案的技术特点,下面通过具体实施方式,对本方案进行阐述。In order to clearly illustrate the technical features of the solution, the solution will be described below through specific implementations.
实施例1:Example 1:
一种黄芩药渣半固体发酵技术方法,半固体发酵技术方法包括以下步骤:A technical method for semi-solid fermentation of Scutellaria baicalensis dregs, the technical method for semi-solid fermentation comprises the following steps:
S1、取黄芩药渣1kg,将黄芩药渣进行挤压,得到含水率为35%的黄芩药渣;S1, get Scutellaria baicalensis dregs 1kg, Scutellaria baicalensis medicinal dregs are squeezed, obtain the Scutellaria baicalensis medicinal dregs with a moisture content of 35%;
S2、将S1步骤得到的含水率为35%的黄芩药渣粉碎至20mm以下,将粉碎后的黄芩药渣压滤,得到含水率为30%的黄芩药渣粉;S2, the Scutellaria baicalensis dregs with a moisture content of 35% obtained in step S1 is pulverized to less than 20 mm, and the pulverized Scutellaria baicalensis dregs are press-filtered to obtain Scutellaria baicalensis dregs powder with a moisture content of 30%;
S3、将S2步骤得到含水率为30%的黄芩药渣粉中加入0.3%重量比的液态植物乳杆菌和0.3%重量比的多种复合酶混合物,并充分混合均匀;S3, adding 0.3% by weight of liquid Lactobacillus plantarum and 0.3% by weight of multiple compound enzyme mixtures in the Scutellaria baicalensis dregs powder with a moisture content of 30% obtained in step S2, and fully mixed;
S4、将S3步骤最终得到的混合物在真空条件下、保持温度在37℃发酵7 天,发酵完成后得到黄芩药渣发酵物并进行真空包装。S4. The mixture finally obtained in step S3 is fermented under vacuum conditions and the temperature is kept at 37° C. for 7 days, and after the fermentation is completed, the fermentation product of Scutellaria baicalensis dregs is obtained and vacuum-packed.
本半固体发酵技术方法制备的黄芩药渣发酵物在存放12个月期间,在外观性状、鉴别、检查、含量各项检查指标均无明显变化,符合临床前药品质量标准的各项规定,质量基本稳定。During the storage period of 12 months, the Scutellaria baicalensis slag fermented product prepared by this semi-solid fermentation technology has no obvious changes in appearance, identification, inspection and content inspection indicators, and meets the requirements of preclinical drug quality standards. Basically stable.
实施例2:Example 2:
一种黄芩药渣半固体发酵技术方法,半固体发酵技术方法包括以下步骤:A technical method for semi-solid fermentation of Scutellaria baicalensis dregs, the technical method for semi-solid fermentation comprises the following steps:
S1、取黄芩药渣1kg,将黄芩药渣进行挤压,得到含水率为70%的黄芩药渣;S1, get Scutellaria baicalensis dregs 1kg, Scutellaria baicalensis medicinal dregs are extruded, obtain the Scutellaria baicalensis medicinal dregs with a moisture content of 70%;
S2、将S1步骤得到的含水率为70%的黄芩药渣粉碎至20mm以下,将粉碎后的黄芩药渣压滤,得到含水率为60%的黄芩药渣粉;S2, the Scutellaria baicalensis dregs with a moisture content of 70% obtained in the step S1 is pulverized to less than 20 mm, and the pulverized Scutellaria baicalensis dregs are press-filtered to obtain the Scutellaria baicalensis dregs powder with a moisture content of 60%;
S3、将S2步骤得到含水率为60%的黄芩药渣粉中加入0.5%重量比的液态植物乳杆菌和0.5%重量比的多种复合酶混合物,并充分混合均匀;S3, adding the liquid Lactobacillus plantarum of 0.5% by weight and the multiple compound enzyme mixture of 0.5% by weight in the Scutellaria baicalensis dregs powder with a moisture content of 60% obtained in step S2, and fully mixing;
S4、将S3步骤最终得到的混合物在真空条件下、保持温度在37℃发酵7 天,发酵完成后得到黄芩药渣发酵物并进行真空包装。S4. The mixture finally obtained in step S3 is fermented under vacuum conditions and the temperature is kept at 37° C. for 7 days, and after the fermentation is completed, the fermentation product of Scutellaria baicalensis dregs is obtained and vacuum-packed.
实施例3:Example 3:
一种黄芩药渣半固体发酵技术方法,半固体发酵技术方法包括以下步骤:A technical method for semi-solid fermentation of Scutellaria baicalensis dregs, the technical method for semi-solid fermentation comprises the following steps:
S1、取黄芩药渣1kg,将黄芩药渣进行挤压,得到含水率为50%的黄芩药渣;S1, get Scutellaria baicalensis dregs 1kg, Scutellaria baicalensis medicinal dregs are extruded, obtain the Scutellaria baicalensis medicinal dregs with a moisture content of 50%;
S2、将S1步骤得到的含水率为50%的黄芩药渣粉碎至20mm以下,将粉碎后的黄芩药渣压滤,得到含水率为45%的黄芩药渣粉;S2, the Scutellaria baicalensis dregs with a moisture content of 50% obtained in step S1 is pulverized to less than 20 mm, and the pulverized Scutellaria baicalensis dregs are pressure-filtered to obtain a Scutellaria baicalensis dregs powder with a moisture content of 45%;
S3、将S2步骤得到含水率为45%的黄芩药渣粉中加入0.4%重量比的液态植物乳杆菌和0.4%重量比的多种复合酶混合物,并充分混合均匀;S3, adding the liquid Lactobacillus plantarum of 0.4% by weight and the multiple compound enzyme mixture of 0.4% by weight in the Scutellaria baicalensis dregs powder with a moisture content of 45% obtained in step S2, and fully mixing;
S4、将S3步骤最终得到的混合物在真空条件下、保持温度在37℃发酵7 天,发酵完成后得到黄芩药渣发酵物并进行真空包装。S4. The mixture finally obtained in step S3 is fermented under vacuum conditions and the temperature is kept at 37° C. for 7 days, and after the fermentation is completed, the fermentation product of Scutellaria baicalensis dregs is obtained and vacuum-packed.
本黄芩药渣半固体发酵技术方法的发明人在发酵技术方法、及其应用方面,进行了一系列实验研究,确定了本黄芩药渣半固体发酵技术方法,使其与现有技术相比具有明显的突出疗效优势。The inventor of this Scutellaria baicalensis dregs semi-solid fermentation technology method has carried out a series of experimental studies on the fermentation technology method and its application, and has determined this Scutellaria baicalensis dregs semi-solid fermentation technical method, which has the advantages of higher efficiency than the prior art. Obvious outstanding therapeutic advantage.
实验一、黄芩药渣半固体发酵物黄酮类成分含量测定Experiment 1. Determination of flavonoids in semi-solid fermentation of Scutellaria baicalensis residues
1、材料1. Materials
1.1、样品:上述实施例1、实施例2和实施例3制备的黄芩药渣发酵物。1.1. Sample: Scutellaria baicalensis dregs fermented product prepared in Example 1, Example 2 and Example 3 above.
1.2、对照物:1.2. Control:
(1)、黄芩药渣;(1), Scutellaria baicalensis dregs;
(2)、将实施例1中S3步骤中最终得到的混合物在真空条件下、保持温度在37℃发酵7天,发酵完成后得到黄芩药渣发酵物并进行真空包装,得到对照发酵物。(2), fermenting the mixture finally obtained in step S3 in Example 1 under vacuum conditions and maintaining the temperature at 37° C. for 7 days, obtaining Scutellaria baicalensis slag fermented product after the fermentation is completed and vacuum-packing to obtain a control fermented product.
2、试验方法2. Test method
2.1、测定方法:高效液相色谱法(通则0512)测定2.1. Determination method: Determination by high performance liquid chromatography (general rule 0512)
2.1.1、色谱条件2.1.1. Chromatographic conditions
色谱柱:以十八烷基硅烷键合硅胶为填充剂;以甲醇-0.1%磷酸为流动相,按下表表1的规定进行梯度洗脱;检测波长为275nm。理论板数按黄芩苷峰计算应不低于2500。Chromatographic column: use octadecylsilane-bonded silica gel as filler; use methanol-0.1% phosphoric acid as mobile phase, and carry out gradient elution as specified in Table 1; detection wavelength is 275 nm. The number of theoretical plates should not be less than 2500 according to the baicalin peak.
表1Table 1
2.2、溶液制备2.2. Solution preparation
对照品溶液的制备:取黄芩苷、汉黄芩苷、黄芩素、汉黄芩素适量,加入甲醇配成100μg/ml的溶液。Preparation of reference solution: take appropriate amount of baicalin, wogonin, baicalein, and wogonin, add methanol to make a solution of 100 μg/ml.
供试品溶液的制备:Preparation of the test solution:
取黄芩药渣粉末2g精密称定,精密加入60%甲醇25ml,超声处理10min,取滤液,即得;Accurately weigh 2 g of Scutellaria baicalensis dregs powder, accurately add 25 ml of 60% methanol, ultrasonically treat for 10 min, and take the filtrate to obtain;
取施例1、实施例2和实施例3制备的黄芩药渣发酵物各2g,精密称定,精密称定,置具塞锥形瓶中,精密加入60%甲醇25ml,密塞,称定重量,超声处理10分钟,放冷,再称定重量,用60%甲醇补足减失的重量,摇匀,滤过,取续滤液,即得。Take 2 g each of the Scutellaria baicalensis slag fermented products prepared in Example 1, Example 2 and Example 3, accurately weigh, accurately weigh, place in a stoppered conical flask, accurately add 25 ml of 60% methanol, close the stopper, and weigh. weight, ultrasonically treated for 10 minutes, allowed to cool, weighed again, used 60% methanol to make up for the lost weight, shaken well, filtered, and the subsequent filtrate was obtained.
2.3、检测方法2.3. Detection method
分别精密量取等量的上述对照品、供试品溶液溶液,注入高效液相色谱仪,进行检测,参照对照品溶液,利用外标法得出检测结果,结果如表2所示。Precisely measure the same amount of the above-mentioned reference substance and the test solution solution, inject it into a high performance liquid chromatograph, and detect it. With reference to the reference substance solution, the external standard method is used to obtain the detection results, and the results are shown in Table 2.
表2黄酮类成分含量Table 2 Contents of flavonoids
3、结论3. Conclusion
从上表2可以看出,实施例1,2和3的效果较好,黄酮类成分含量提高了2倍,尤其是黄芩素的含量有了大幅提升,黄芩素具有降低脑血管阻力,改善脑血循环、增加脑血流量及抗血小板凝集的作用。临床用于脑血管病后瘫痪的治疗。黄芩素进入动物体内后,在血液中迅速转化为黄芩苷及其他代谢物。发酵10天的对照发酵物样品与实施例1相比,黄酮类成分总含量较实施例1 发酵7天的样品有所下降,因此从节约成本的角度出发,认为发酵7天即可。As can be seen from the above table 2, the effects of Examples 1, 2 and 3 are better, the content of flavonoids is increased by 2 times, especially the content of baicalein has been greatly improved, and baicalein can reduce cerebral vascular resistance, improve brain Blood circulation, increase cerebral blood flow and anti-platelet aggregation. Clinically used for the treatment of paralysis after cerebrovascular disease. After baicalein enters the animal body, it is rapidly converted into baicalin and other metabolites in the blood. Compared with Example 1, the total content of flavonoids in the control fermented sample fermented for 10 days is lower than that of the sample fermented for 7 days in Example 1. Therefore, from the perspective of cost saving, it is considered that fermentation for 7 days is sufficient.
实验二、本发明中黄芩药渣半固体发酵物抑菌实验Experiment 2. Antibacterial experiment of Scutellaria baicalensis dregs semi-solid fermentation product in the present invention
1样品1 sample
1.1菌株1.1 Strains
大肠杆菌O78标准菌株(E.coli O78,编号CVCC1418);金黄色葡萄球菌菌株ATCC29213。Escherichia coli O78 standard strain (E. coli O78, number CVCC1418); Staphylococcus aureus strain ATCC29213.
1.2样品与试剂1.2 Samples and Reagents
样品:实施例1、实施例2和实施例3制备的黄芩药渣发酵物、黄芩药渣样品。Samples: Scutellaria baicalensis dregs fermentation product and Scutellaria baicalensis dregs samples prepared in Example 1, Example 2 and Example 3.
试剂:营养肉汤培养基,麦康凯培养基,普通营养琼脂培养基、乙醇等试剂均为分析纯。Reagents: Nutrient broth medium, MacConkey medium, common nutrient agar medium, ethanol and other reagents are of analytical grade.
1.3仪器1.3 Instruments
循环真空水泵(SHZ-3型)、真空干燥箱(ZK-82B型)、电子控温电热器、高压蒸汽灭菌锅、电子分析天平(FA1004型)、回流冷凝装置、蒸馏装置等。Circulating vacuum water pump (SHZ-3 type), vacuum drying oven (ZK-82B type), electronic temperature control electric heater, high pressure steam sterilizer, electronic analytical balance (FA1004 type), reflux condensing device, distillation device, etc.
2、方法2. Method
2.1菌液的制备2.1 Preparation of bacterial solution
将标准大肠杆菌和金黄色葡萄球菌划线于固体培养基上,于37℃培养18~ 24h。分别挑取单个菌落接种于营养肉汤培养基中,于37℃培养18h。用平皿稀释法测定菌液的浓度,调整细菌浓度为1.5×108CFU/ml备用。Standard Escherichia coli and Staphylococcus aureus were streaked on the solid medium and cultured at 37°C for 18-24h. A single colony was picked and inoculated into the nutrient broth medium and cultured at 37°C for 18h. Determine the concentration of the bacterial solution by the plate dilution method, and adjust the bacterial concentration to 1.5×10 8 CFU/ml for later use.
2.2试验样品的制备2.2 Preparation of test samples
取实施例1,2,3制备的黄芩药渣发酵物和黄芩药渣样品进行水煎提取,加 10倍量的水提取1h后,浓缩至含药量为1g/ml的溶液,置于小瓶,120℃高压灭菌20min,置4℃冰箱备用。Take the Scutellaria baicalensis dregs fermentation product and Scutellaria baicalensis dregs samples prepared in Examples 1, 2, and 3 for decoction extraction, add 10 times the amount of water for extraction for 1 h, concentrate to a solution containing 1 g/ml of drug, and place in a vial , 120 ℃ high pressure sterilization 20min, set aside 4 ℃ refrigerator.
2.3最低抑菌浓度MIC值的测定2.3 Determination of the minimum inhibitory concentration MIC value
设置四组实验组(包括Ⅰ、Ⅱ、Ⅲ、Ⅳ组),每组实验组均取小试管12支并编号;用无菌移液枪于每支试管中加普通营养肉汤培养基1ml;无菌条件下于第一管加入试验药物1ml,震荡混匀;吸取试验药物1ml加入第二管中震荡混匀,依次类推至第11管,吸取1ml弃去(保证12支试管中的溶液体积相同),第12管不加作为阳性对照。每管加入上述制备的菌液1ml,置37℃孵育箱,培养18h后观察试验结果,生长管的前一管为该样品的MIC。试验重复3次取其平均值作为每个样品的MIC值;Four experimental groups (including Ⅰ, Ⅱ, Ⅲ, Ⅳ groups) were set up, and 12 small test tubes were taken and numbered in each experimental group; 1 ml of ordinary nutrient broth medium was added to each test tube with a sterile pipette; Add 1ml of the test drug to the first tube under aseptic conditions, shake and mix; draw 1ml of the test drug and add it to the second tube, shake and mix, and so on to the 11th tube, draw 1ml and discard (guarantee the volume of the solution in the 12 test tubes). The same), the 12th tube was not added as a positive control. Add 1 ml of the above-prepared bacterial solution to each tube, set it in a 37°C incubator, and observe the test results after culturing for 18 hours. The previous tube of the growth tube is the MIC of the sample. The test was repeated 3 times and the average value was taken as the MIC value of each sample;
其中,Ⅰ组中使用由实施例1黄芩药渣发酵物制备的试验药物,Ⅱ组中使用由实施例2黄芩药渣发酵物制备的试验药物,Ⅲ组中使用由实施例3黄芩药渣发酵物制备的试验药物,Ⅳ组中使用由黄芩药渣样品制备的试验药物。Wherein, the test drug prepared from the fermentation product of Scutellaria baicalensis in Example 1 was used in group I, the test drug prepared from the fermentation product of Scutellaria baicalensis in Example 2 was used in group II, and the test drug prepared from the fermentation product of Scutellaria baicalensis in Example 3 was used in group III. The experimental drug prepared from the scutellaria baicalensis drug residue was used in group IV.
3、结果3. Results
实验组Ⅰ、Ⅱ、Ⅲ、Ⅳ组对大肠杆菌和金黄色葡萄球菌的体外抑菌效果见表3:The in vitro antibacterial effects of experimental groups I, II, III, and IV on Escherichia coli and Staphylococcus aureus are shown in Table 3:
表3体外抑菌效果Table 3 In vitro antibacterial effect
从表3中可以看出Ⅰ、Ⅱ、Ⅲ、Ⅳ组对大肠杆菌等革兰氏阴性菌和金黄色葡萄球菌等革兰氏阳性菌均有一定的抑菌效果。其中Ⅰ的抑菌效果最好,最低抑菌浓度可达156mg/ml;其次为Ⅲ组的抑菌效果也较好,抑菌浓度为225mg/ml;Ⅱ、Ⅳ组的抑菌效果最差,其抑菌浓度均超过1000mg/ml。It can be seen from Table 3 that groups I, II, III and IV have certain bacteriostatic effects on gram-negative bacteria such as Escherichia coli and gram-positive bacteria such as Staphylococcus aureus. Among them, the antibacterial effect of group I was the best, and the minimum inhibitory concentration could reach 156 mg/ml; the second was group III, which had better antibacterial effect, with an inhibitory concentration of 225 mg/ml; the antibacterial effect of groups II and IV was the worst. The inhibitory concentration was more than 1000mg/ml.
实验三、本发明中黄芩药渣半固体发酵物急毒评价实验Experiment 3. Acute toxicity evaluation experiment of Scutellaria baicalensis dregs semi-solid fermentation product in the present invention
取实施例1,2,3和黄芩药渣粉末,进行水煎提取,加10倍量的水提取1h 后,浓缩至含药量为200mg/ml的溶液。每只小鼠按5g/kg b.wt.灌胃给予各样品1次,灌胃体积为0.2ml/10g,给药后连续观察4h,之后连续观察7d,在观察期内各动物精神状态、毛色、自主活动、呼吸、饮食、二便、口鼻分泌物等一般状态未见异常,无动物死亡,且体重自然增长。试验结束后将小鼠脱臼处死,主要脏器均无肉眼可见病变,无明显中毒表现或不良反应。表明本发酵产物对昆明种小鼠的LD50大于5g/kg,根据WTO有关外源性化学物急性毒性分级标准进行评价,试验结果表明本发酵产物属实际无毒。Take Examples 1, 2, 3 and Scutellaria baicalensis powder, decoct and extract in water, add 10 times the amount of water to extract for 1 hour, and then concentrate to a solution with a drug content of 200 mg/ml. Each mouse was given each sample by gavage at 5g/kg b.wt. once, and the gavage volume was 0.2ml/10g. After administration, the mice were continuously observed for 4 hours and then for 7 days. During the observation period, the mental state, There was no abnormality in the general state of coat color, autonomous activity, breathing, diet, feces, oral and nasal secretions, and no animal died, and the body weight increased naturally. After the experiment, the mice were killed by dislocation. There were no visible lesions in the main organs, and no obvious poisoning or adverse reactions. It shows that the LD 50 of the fermentation product to Kunming mice is greater than 5g/kg. According to the WTO classification standard of acute toxicity of exogenous chemicals, the test results show that the fermentation product is actually non-toxic.
本发明未经描述的技术特征可以通过或采用现有技术实现,在此不再赘述,当然,上述说明并非是对本发明的限制,本发明也并不仅限于上述举例,本技术领域的普通技术人员在本发明的实质范围内所做出的变化、改型、添加或替换,也应属于本发明的保护范围。The undescribed technical features of the present invention can be realized by or using the existing technology, and will not be repeated here. Of course, the above description is not a limitation of the present invention, and the present invention is not limited to the above examples. Those skilled in the art Changes, modifications, additions or substitutions made within the essential scope of the present invention shall also belong to the protection scope of the present invention.
Claims (4)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019105384513 | 2019-06-20 | ||
| CN201910538451.3A CN110251558A (en) | 2019-06-20 | 2019-06-20 | A kind of radix scutellariae dregs of a decoction semisolid fermentation technical method and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111265565A true CN111265565A (en) | 2020-06-12 |
Family
ID=67919883
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910538451.3A Withdrawn CN110251558A (en) | 2019-06-20 | 2019-06-20 | A kind of radix scutellariae dregs of a decoction semisolid fermentation technical method and its application |
| CN202010188045.1A Pending CN111265565A (en) | 2019-06-20 | 2020-03-17 | A kind of Scutellaria baicalensis dregs semi-solid fermentation technology method and its application |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910538451.3A Withdrawn CN110251558A (en) | 2019-06-20 | 2019-06-20 | A kind of radix scutellariae dregs of a decoction semisolid fermentation technical method and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN110251558A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112931690A (en) * | 2021-03-08 | 2021-06-11 | 黑龙江省科学院微生物研究所 | Piglet feed additive and preparation method thereof |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110583871A (en) * | 2019-09-30 | 2019-12-20 | 中国农业科学院兰州畜牧与兽药研究所 | Biological fermentation product of traditional Chinese medicine residue of Maiwei rehmannia pills and preparation method and application thereof |
| CN111024853B (en) * | 2019-12-29 | 2022-07-29 | 山西中医药大学 | Fermentation method for quickly converting baicalin into baicalein |
| CN113215024B (en) * | 2021-03-08 | 2023-07-04 | 黑龙江省科学院微生物研究所 | Lactobacillus plantarum and method for fermenting baical skullcap root dregs |
| CN116287009B (en) * | 2022-12-16 | 2026-02-27 | 北京挑战农业科技有限公司 | Production method and application of Shuanghuanglian residue co-fermentation by Bacillus vesiculosus and Pediococcus lactis |
-
2019
- 2019-06-20 CN CN201910538451.3A patent/CN110251558A/en not_active Withdrawn
-
2020
- 2020-03-17 CN CN202010188045.1A patent/CN111265565A/en active Pending
Non-Patent Citations (4)
| Title |
|---|
| 冷桂华: "黄芩及其提取药渣黄芩苷含量的比较", 《安徽农业科学》 * |
| 喻春皓等: "纤维素酶辅助提取生黄芩饮片中黄酮苷元的工艺研究", 《安徽农业科学》 * |
| 杨威: "超声波提取黄芩药渣中的黄芩苷", 《化学与粘合》 * |
| 王耀新等: "中药发酵技术研究概况", 《中医药信息》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112931690A (en) * | 2021-03-08 | 2021-06-11 | 黑龙江省科学院微生物研究所 | Piglet feed additive and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110251558A (en) | 2019-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111265565A (en) | A kind of Scutellaria baicalensis dregs semi-solid fermentation technology method and its application | |
| CN103027953B (en) | Extractive containing total meroterpenoid of psidium guajave dialdehyde, and preparation method and application thereof | |
| CN106942724B (en) | Composition with function of regulating intestinal flora structure and preparation method and application thereof | |
| WO2012097575A1 (en) | Method for preparing pharmaceutical composition for enhancing immunity and pharmaceutical composition prepared according to the method | |
| CN114984114B (en) | Liquid fermentation traditional Chinese medicine microecological preparation and application thereof in aspect of resisting porcine epidemic diarrhea virus | |
| CN103555641A (en) | Mycoplasma hyopneumoniae culture medium and preparation method thereof | |
| CN103494797A (en) | Composition of peony seed total stilbene compounds as well as extraction method and application thereof | |
| CN102824417B (en) | New method for treating helicobacter pylori related diseases | |
| CN112156156A (en) | Veterinary traditional Chinese medicine antiviral oral liquid and preparation method thereof | |
| CN103211098B (en) | Aflatoxin adsorbent and application | |
| CN104257826A (en) | Traditional Chinese medicine pycnonotus sinensis fermented granule for livestock and poultry and preparation method of traditional Chinese medicine pycnonotus sinensis fermented granule | |
| CN103550401B (en) | A kind of preparation method of composite microbial ecological agent effervescent tablet | |
| CN113181229B (en) | Application of cabbage type rape-isatis tinctoria G monomer addition system in inhibiting novel coronavirus SARS-CoV-2 | |
| CN102552369B (en) | Lon icera japonica Thunb leaf extractive serving as anti-porcine reproductive and respiratory syndrome viral agent | |
| CN110711212A (en) | Astragalus root-paecilomyces cicadae fermentation mycoplasm and application thereof | |
| CN101612204B (en) | Streptococcus suis resistance inhibitor | |
| CN114391603A (en) | Feeding traditional Chinese medicine microecological preparation and preparation method thereof | |
| CN114681530B (en) | Application of traditional Chinese medicine composition or fermentation product thereof, animal feed and animal feed additive | |
| CN104306492A (en) | Drug with anti-bacterial and synergistically anti-bacterial activity, and preparation method and application thereof | |
| CN117343877A (en) | Bacillus amyloliquefaciens MHDS-1 and application thereof in Taxus media processing | |
| CN103550770B (en) | Preparation method of compound effervescent tablets for treating chicken infectious bursal disease | |
| CN103110673B (en) | Antimicrobial total triterpenoid saponin of pubescent holly root and application of antimicrobial total triterpenoid saponin | |
| CN106913670B (en) | Growth-promoting and strong immunity traditional Chinese medicine biological preparation for poultry and preparation method thereof | |
| CN117224587B (en) | Erigeron breviscapus extract and preparation method and application thereof | |
| CN117298212B (en) | Composition for preventing and treating mammitis and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20201214 Address after: 15-1-801, phase II, Hisense Huiyuan, No.7, Jiangxi Road, Shinan District, Qingdao City, Shandong Province Applicant after: Zhong Yingjie Address before: Room 705, building 19, doctor Pioneer Park, Chengyang street, Chengyang District, Qingdao City, Shandong Province Applicant before: Qingdao Rongtai Biotechnology Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200612 |
|
| RJ01 | Rejection of invention patent application after publication |


